Eli Lilly's weight loss drug could help sleep apnea patients

Yahoo Finance Video
24,913 次觀看・7 個月前

Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep.

The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use.

Yahoo Finance's Anjalee Khemlani breaks down the details.

For more expert insight and the latest market action, click here to watch this full episode.

This post was written by Angel Smith